Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
Epigenetic reprogramming of the androgen receptor (AR) has been identified as an important process driving prostate cancer (PCa) progression. Here, the authors analyze the role of AR chromatin binding heterogeneity in PCa clinical outcomes, metastasis and relapse.
Main Authors: | Jeroen Kneppers, Tesa M. Severson, Joseph C. Siefert, Pieter Schol, Stacey E. P. Joosten, Ivan Pak Lok Yu, Chia-Chi Flora Huang, Tunç Morova, Umut Berkay Altıntaş, Claudia Giambartolomei, Ji-Heui Seo, Sylvan C. Baca, Isa Carneiro, Eldon Emberly, Bogdan Pasaniuc, Carmen Jerónimo, Rui Henrique, Matthew L. Freedman, Lodewyk F. A. Wessels, Nathan A. Lack, Andries M. Bergman, Wilbert Zwart |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-35135-2 |
Similar Items
-
Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
by: Ekaterina Nevedomskaya, et al.
Published: (2014-12-01) -
Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
by: Tesa M. Severson, et al.
Published: (2021-07-01) -
Functional mapping of androgen receptor enhancer activity
by: Chia-Chi Flora Huang, et al.
Published: (2021-05-01) -
Androgen Receptor-Mediated Transcription in Prostate Cancer
by: Doğancan Özturan, et al.
Published: (2022-03-01) -
Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
by: Yongsoo Kim, et al.
Published: (2019-11-01)